Other Information
−Removed: During the three months ended June 30, 2025, the following officer adopted Rule 10b5-1 trading arrangements (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
−Removed: Trading Arrangement
−Removed: Name and Title
−Removed: Non-Rule 10b5-1**
−Removed: Total Shares To Be Sold
−Removed: Expiration Date
−Removed: Bernadette Connaughton
−Removed: 17,330 8/31/2026
−Removed: Nicole LaBrosse
−Removed: Senior Vice President and Chief Financial Officer
−Removed: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
−Removed: ** Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act.
−Removed: *** The total number of shares to be sold under this plan is 22,227 plus an undetermined number of shares to be sold resulting from the vesting of 17,110 restricted stock units less the amount of shares that will be withheld to satisfy the payment of tax withholding obligations due upon vesting.
+Added: During the three months ended September 30, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408 of Regulation S-K).
+Added: 2.1 Agreement and Plan of Merger, among Halozyme Therapeutics, Inc., Erraid Merger Sub Inc., Elektrofi, Inc.
+Added: and Shareholder Representative Services LLC, solely in its capacity as the representative of the securityholders as set forth in the Merger Agreement dated as of September 30, 2025 (filed as Exhibit 2.1 to the C ompany ’ s F orm 8-K filed October 3, 2025 and incorporated herein by refer ence)
3.1 Amended and Restated Certificate of Incorporation of Halozyme Therapeutics, Inc.
22 unchanged sentences
Halozyme Therapeutics, Inc.
−Removed: August 5, 2025 By:
+Added: November 3, 2025 By:
Ch.B., M.R.C.P.
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 5, 2025 By:
+Added: November 3, 2025 By:
/s/ Nicole LaBrosse
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.